Trial reportJournal of diabetes science and technology2016
Efficacy of an Overnight Predictive Low-Glucose Suspend System in Relation to Hypoglycemia Risk Factors in Youth and Adults With Type 1 Diabetes.
Trial report in Journal of diabetes science and technology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 19 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 2 syntheses or guidelines pooled it, 39 citations in OpenAlex.
- Perioperative use and accuracy of continuous glucose monitoring: A systematic review.Diabetes, obesity & metabolism · 2025Pooled it
- 2023 Clinical Practice Guidelines for Diabetes Management in Korea: Full Version Recommendation of the Korean Diabetes Association.Diabetes & metabolism journal · 2024Guideline
- Metabolic Responses to Exercise and Nutritional Strategies in Type 1 Diabetes Using Automated Insulin Delivery Systems: A Narrative Review.Metabolites · 2026Review
- 2025 Clinical Practice Guidelines for Diabetes Management in Korea: Recommendation of the Korean Diabetes Association.Diabetes & metabolism journal · 2025Article
- An automatic deep reinforcement learning bolus calculator for automated insulin delivery systems.Scientific reports · 2024Article
- Utility and precision evidence of technology in the treatment of type 1 diabetes: a systematic review.Communications medicine · 2023Article
- Technological Ecological Momentary Assessment Tools to Study Type 1 Diabetes in Youth: Viewpoint of Methodologies.JMIR diabetes · 2021Article
- Modern diabetes devices in the school setting: Perspectives from school nurses.Pediatric diabetes · 2020Article
- Recreational diving in persons with type 1 and type 2 diabetes: Advancing capabilities and recommendations.Diving and hyperbaric medicine · 2020Review
- Artificial Intelligence in Decision Support Systems for Type 1 Diabetes.Sensors (Basel, Switzerland) · 2020Review
- The hypoglycemia-prevention effect of sensor-augmented pump therapy with predictive low glucose management in Japanese patients with type 1 diabetes mellitus: a short-term study.Diabetology international · 2020Article
- Automated Insulin Delivery in Adults.Endocrinology and metabolism clinics of North America · 2020Review
- One Year Clinical Experience of the First Commercial Hybrid Closed-Loop System.Diabetes care · 2019Observational
- Artificial Pancreas: Current Progress and Future Outlook in the Treatment of Type 1 Diabetes.Drugs · 2019Review
- Insulin delivery and nocturnal glucose control in children and adolescents with type 1 diabetes.Expert opinion on drug delivery · 2017Review
- Discrepancies Between Blood Glucose and Interstitial Glucose-Technological Artifacts or Physiology: Implications for Selection of the Appropriate Therapeutic Target.Journal of diabetes science and technology · 2017Article
- Continuous Glucose Monitoring: A Review of Recent Studies Demonstrating Improved Glycemic Outcomes.Diabetes technology & therapeutics · 2017Review
- "Let the Algorithm Do the Work": Reduction of Hypoglycemia Using Sensor-Augmented Pump Therapy with Predictive Insulin Suspension (SmartGuard) in Pediatric Type 1 Diabetes Patients.Diabetes technology & therapeutics · 2017Article
- An Adaptive Nonlinear Basal-Bolus Calculator for Patients With Type 1 Diabetes.Journal of diabetes science and technology · 2017Article
Corrections and comments
- Commented on byCorrigendum.2017
- Erratum issuedCorrigendum.2017
Authors and funding
13 authors at 4 institutions in 2 countries.
Funding
Abstract
backgroundWe developed a system to suspend insulin pump delivery overnight when the glucose trend predicts hypoglycemia. This predictive low-glucose suspend (PLGS) system substantially reduces nocturnal hypoglycemia without an increase in morning ketosis. Evaluation of hypoglycemia risk factors that could potentially influence the efficacy of the system remains critical for understanding possible problems with the system and identifying patients that may have the greatest benefit when using the system.
methodsThe at-home randomized trial consisted of 127 study participants with hemoglobin A1c (A1C) of ≤8.5% (mmol/mol) for patients aged 4-14 years and ≤8.0% for patient aged 15-45 years. Factors assessed included age, gender, A1C, diabetes duration, daily percentage basal insulin, total daily dose of insulin (units/kg-day), bedtime BG, bedtime snack, insulin on board, continuous glucose monitor (CGM) rate of change (ROC), day of the week, time system activated, daytime exercise intensity, and daytime CGM-measured hypoglycemia.
resultsThe PLGS system was effective in preventing hypoglycemia for each factor subgroup. There was no evidence that the PLGS system was more or less effective in preventing hypoglycemia in any one subgroup compared with the other subgroups based on that factor. In addition, the effect of the system on overnight hyperglycemia did not differ in subgroups.
conclusionsThe PLGS system tested in this study effectively reduced hypoglycemia without a meaningful increase in hyperglycemia across a variety of factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.